Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

nice_reception

NICE rules Shire’s Onivyde not cost effective

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, Onivyde, Shire

Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …
News
images

NICE approves Roche’s Perjeta for breast cancer

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer

NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …
News

Myelofibrosis market to increase to be worth over $1 billion by 2025

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis

The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …
News
placebo

Surprising number of parents agree to use of placebos in children

November 16, 2016 Medical Communications, Research and Development Placebo, children

A study by Boston Children’s Hospital found that parents recognised that placebos are a vital part of research and that …
News
shutterstock_292920209

Real world evidence: a reality check for pharma?

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing real world evidence

Rising demands on the industry has pharma firms calling for a more-effective, fit-for-purpose methodology for generating clinical data. Could the …
Feature
msd

Powerful new data for MSD’s bladder cancer drug stops trial early

November 16, 2016 Research and Development MSD, pembrolizumab

MSD has released new data which reinforces the efficacy of its anti-PD-1 therapy pembrolizumab in patients with advanced urothelial (bladder) …
News

Abbott-St. Jude $25 billion deal close to clearance

November 16, 2016 Research and Development, Sales and Marketing Abbott, St. Jude, acquisition

EU antitrust regulators are due to reach a decision on the deal on 23 November that would see Abbott Laboratories …
News
janssen_latest_logo_on_sign_closer

Janssen’s Crohn’s treatment licensed for UK use

November 16, 2016 Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara

Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …
News
celgene_1_02

NICE rejects Celegene’s Revlimid as second-line treatment

November 16, 2016 Research and Development, Sales and Marketing Celegene, Revlimid

NICE has decided Celegene’s multiple myeloma growth engine Revlimid (lenalidomide) will not be offered to patients as a second line …
News
nordic-nanovector-big

New CMO and Executive Management Team member for Nordic Nanovector

November 15, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Nordic Nanovector has recruited a new chief medical officer (CMO) and Executive Management Team member with the appointment of Dr …
Appointment
celgene_1_02

Celgene’s Otezla hits primary endpoint in psoriatic arthritis study

November 15, 2016 Manufacturing and Production, Research and Development Celgene, otezla, psoriatic arthritis

Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment …
News
abbvie_0

AbbVie investigational hep C drug boasts 97.5% response rate

November 15, 2016 Manufacturing and Production, Medical Communications, Research and Development AbbVie, hepatitis C, pan-genotypic

AbbVie released details on their latest trials for their investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530). In an eight week …
News

Novartis reveals positive three-year efficacy data for psoriatic arthritis drug

November 15, 2016 Manufacturing and Production, Research and Development Cosentyx, Novartis, psoriatic arthritis

Novartis has claimed that its Cosentyx (secukinumab) treatment is now the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate …
News
adriane_brown

Allergan appoints Adriane M. Brown to board of directors

November 14, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan

Allergan announced that Adriana M. Brown will join its board of directors on February 2017. Adriana Brown is currently the …
Appointment

Free Pharmacovigilance Webinar: Available to view now!

November 14, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Webinar, pharmacovigilance, primevigilance

Pharmafocus, alongside PrimeVigilance, hosted a webinar on 10 November and is now available to view for free.Throughout the webinar, PrimeVigilance …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025